Transplantation, AutologousHematopoietic Stem Cell TransplantationStem Cell TransplantationPeripheral Blood Stem Cell TransplantationMultiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsMelphalanTransplantation, HomologousTransplantation ConditioningCombined Modality TherapyTreatment OutcomeRemission InductionStem CellsSalvage TherapyDisease-Free SurvivalEtoposideHodgkin DiseaseCyclophosphamideLymphoma, Non-HodgkinMyeloablative AgonistsRecurrenceCytarabineCarmustineSurvival RateHematopoietic Stem Cell MobilizationBone Marrow TransplantationGraft vs Host DiseaseThiotepaVincristineBone Marrow PurgingSurvival AnalysisHematologic NeoplasmsRetrospective StudiesLymphoma, Mantle-CellWhole-Body IrradiationAmyloidosisDoxorubicinHematopoietic Stem CellsPrognosisBusulfanBoronic AcidsDexamethasonePyrazinesGraft SurvivalFollow-Up StudiesAntibodies, Monoclonal, Murine-DerivedLymphoma, FollicularAntineoplastic Agents, AlkylatingAntigens, CD34AutograftsLymphoma, T-Cell, PeripheralLiver TransplantationThalidomideIfosfamideAntineoplastic AgentsTime FactorsInduction ChemotherapyMesenchymal Stem Cell TransplantationGranulocyte Colony-Stimulating FactorLeukapheresisLymphomaPrednisonePodophyllotoxinLymphoma, Large B-Cell, DiffuseNeoplasm, ResidualTransplantation ChimeraMaintenance ChemotherapyTissue DonorsLeukemia, Myeloid, AcuteCord Blood Stem Cell TransplantationCell TransplantationKidney TransplantationLymphoma, B-CellEnteropathy-Associated T-Cell LymphomaMyelodysplastic SyndromesEmbryonic Stem CellsMitoxantroneIdarubicinProspective StudiesNeoplasms, Second PrimaryLeukemia, Plasma CellInfusions, SpinalCisplatinCarboplatinAdult Stem CellsBlood Component RemovalImmunosuppressive AgentsChemotherapy, AdjuvantNeoplasm Recurrence, LocalHistocompatibility TestingFatal OutcomeAntibodies, MonoclonalFeasibility StudiesDrug Administration ScheduleLeukemia, MyeloidRisk FactorsCell DifferentiationKeratins, Type IILife TablesNeutropenia